Karl-Norbert Klotz

List of Publications by Year
in descending order

145 papers	5,715 citations	66343 42 h-index	91884 69 g-index
154 all docs	154 docs citations	154 times ranked	5059 citing authors

#	Article	IF	Citations
1	8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) ? a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1987, 336, 204-210.	3.0	367
2	Adenosine receptors and their ligands. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 362, 382-391.	3.0	284
3	Comparative pharmacology of human ï¿½-adrenergic receptor subtypes?characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 151-159.	3.0	279
4	Analysis of receptor oligomerization by FRAP microscopy. Nature Methods, 2009, 6, 225-230.	19.0	187
5	Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunology, Immunotherapy, 2011, 60, 1405-1418.	4.2	163
6	The Small Antitumoral Immune Response Modifier Imiquimod Interacts with Adenosine Receptor Signaling in a TLR7- and TLR8-Independent Fashion. Journal of Investigative Dermatology, 2006, 126, 1338-1347.	0.7	138
7	Adenosine Receptors as Mediators of Both Cell Proliferation and Cell Death of Cultured Human Melanoma Cells. Journal of Investigative Dermatology, 2002, 119, 923-933.	0.7	134
8	Water-Soluble Phosphate Prodrugs of 1-Propargyl-8-styrylxanthine Derivatives, A2A-Selective Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 440-448.	6.4	129
9	2-Chloro-N6-[3H]cyclopentyladenosine ([3HCCPA) ?a high affinity agonist radioligand for A1 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1989, 340, 679-683.	3.0	124
10	2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 337, 687-9.	3.0	120
11	Adenosine A₁Receptor-Mediated Activation of Phospholipase C in Cultured Astrocytes Depends on the Level of Receptor Expression. Journal of Neuroscience, 1997, 17, 4956-4964.	3.6	114
12	N6-Alkyl-2-alkynyl Derivatives of Adenosine as Potent and Selective Agonists at the Human Adenosine A3Receptor and a Starting Point for Searching A2BLigands. Journal of Medicinal Chemistry, 2002, 45, 3271-3279.	6.4	104
13	Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2002, 45, 770-780.	6.4	99
14	2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors. Journal of Medicinal Chemistry, 1992, 35, 2363-2368.	6.4	98
15	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists:Â Influence of the Chain at the N8Pyrazole Nitrogen. Journal of Medicinal Chemistry, 2000, 43, 4768-4780.	6.4	89
16	New substituted 9-alkylpurines as adenosine receptor ligands. Bioorganic and Medicinal Chemistry, 1998, 6, 523-533.	3.0	82
17	synthesis of new Î" 2 -isoxazoline derivatives and their pharmacological characterization as Î²-adrenergic receptor antagonists. Bioorganic and Medicinal Chemistry, 1998, 6, 401-408.	3.0	81
18	Medicinal Chemistry and Pharmacology of A2B Adenosine Receptors. Current Topics in Medicinal Chemistry, 2003, 3, 427-443.	2.1	81

#	Article	IF	Citations
19	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 4473-4478.	6.4	80
20	Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. British Journal of Pharmacology, 2005, 145, 211-218.	5.4	65
21	Role of the Î²1-Adrenergic Pathway in Anesthetic and Ischemic Preconditioning against Myocardial Infarction in the Rabbit Heart In VivoÂ. Anesthesiology, 2006, 105, 503-510.	2.5	64
22	[3H]HEMADOâ€" a novel tritiated agonist selective for the human adenosine A3 receptor. European Journal of Pharmacology, 2007, 556, 14-18.	3.5	60
23	Neutrophil chemoattractant receptors and the membrane skeleton. BioEssays, 1994, 16, 193-198.	2.5	59
24	Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20. Molecular Pharmacology, 2005, 67, 2137-2147.	2.3	58
25	Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 337, 64-8.	3.0	55
26	Improving Potency, Selectivity, and Water Solubility of Adenosineâ€…A1 Receptor Antagonists: Xanthines Modified at Positionâ€…3 and Related Pyrimido[1,2,3-cd]purinediones. ChemMedChem, 2006, 1, 891-902.	3.2	54
27	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochemical Pharmacology, 2005, 70, 1601-1612.	4.4	53
28	Cytoskeletal regulation of chemotactic receptors: Molecular complexation of Nâ€formyl peptide receptors with G proteins and actin. European Journal of Haematology, 1993, 51, 288-293.	2.2	53
29	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorganic and Medicinal Chemistry, 2009, 17, 2812-2822.	3.0	53
30	Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. European Journal of Pharmacology, 1991, 206, 285-290.	2.6	52
31	Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. Naunyn-Schmiedeberg's Archives of Pharmacology, 1991, 343, 196-201.	3.0	52
32	Agonist-Induced Internalization and Recycling of the Human A3 Adenosine Receptors. Journal of Neurochemistry, 2002, 75, 1493-1501.	3.9	52
33	Characterization of the Solubilized A1Adenosine Receptor from Rat Brain Membranes. Journal of Neurochemistry, 1986, 46, 1528-1534.	3.9	51
34	A New Synthesis of Sulfonamides by Aminolysis ofp-Nitrophenylsulfonates Yielding Potent and Selective Adenosine A2BReceptor Antagonists. Journal of Medicinal Chemistry, 2006, 49, 4384-4391.	6.4	50
35	Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogs of adenosine derivatives. Journal of Medicinal Chemistry, 1988, 31, 1179-1183.	6.4	49
36	7-Deazaadenines Bearing Polar Substituents:â€‰ Structureâ€'Activity Relationships of New A1 and A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 4636-4646.	6.4	49

#	Article	IF	Citations
37	2-(Benzimidazol-2-yl)quinoxalines:Â A Novel Class of Selective Antagonists at Human A1and A3Adenosine Receptors Designed by 3D Database Searching. Journal of Medicinal Chemistry, 2005, 48, 8253-8260.	6.4	49
38	2-Substituted N -ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A 3 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360, 103-108.	3.0	48
39	8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists11Preliminary results were presented at the International Symposium â€œPurines â€™96â€•in Milan, Italy; abstract published in Drug Dev. Res. 1996, 37, 112.. Bioorganic and Medicinal Chemistry, 1998, 6, 707-719.	3.0	46
40	Discovery of novel A3 adenosine receptor ligands based on chromone scaffold. Biochemical Pharmacology, 2012, 84, 21-29.	4.4	46
41	N6-Cycloalkyl- and N6-Bicycloalkyl-C5â€²(C2â€²)-modified Adenosine Derivatives as High-Affinity and Selective Agonists at the Human A1 Adenosine Receptor with Antinociceptive Effects in Mice. Journal of Medicinal Chemistry, 2009, 52, 2393-2406.	6.4	44
42	Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists. Journal of Pharmacy and Pharmacology, 2013, 65, 697-703.	2.4	44
43	Reduction of postischemic leukocyte-endothelium interaction by adenosine via A2 receptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 346, 234-237.	3.0	43
44	2â€²,3â€²-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. European Journal of Pharmacology, 1988, 156, 157-160.	3.5	40
45	Effector coupling of stably transfected human A3 adenosine receptors in CHO cells. Biochemical Pharmacology, 2002, 64, 61-65.	4.4	40
46	The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA₃ Adenosine Receptors Antagonists: New Insights into Structureâ^'Affinity Relationship and Receptorâ^'Antagonist Recognition. Journal of Medicinal Chemistry, 2010, 53, 3361-3375.	6.4	40
47	Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives. Current Pharmaceutical Design, 2019, 25, 2697-2715.	1.9	39
48	Involvement of mitogen protein kinase cascade in agonist-mediated human A3 adenosine receptor regulation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1591, 55-62.	4.1	38
49	N6-Methoxy-2-alkynyladenosine Derivatives as Highly Potent and Selective Ligands at the Human A3 Adenosine Receptor. Journal of Medicinal Chemistry, 2007, 50, 1222-1230.	6.4	38
50	Characterization of potent ligands at human recombinant adenosine receptors. Drug Development Research, 1998, 45, 176-181.	2.9	34
51	Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists. Journal of Medicinal Chemistry, 2005, 48, 1550-1562.	6.4	34
52	Synthesis and Biological Evaluation of 2-Alkynyl-N6-methyl-5â€²-N-methylcarboxamidoadenosine Derivatives as Potent and Highly Selective Agonists for the Human Adenosine A3Receptorâ€¡. Journal of Medicinal Chemistry, 2009, 52, 7897-7900.	6.4	34
53	9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 629-634.	3.0	33
54	Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3-d]pyrimidine derivatives. Chemical Biology and Drug Design, 2018, 91, 962-969.	3.2	33

#	Article	IF	Citations
55	Adenosine A_{2A} Receptor Antagonists: New 8â€Substituted 9â€Ethyladenines as Tools for inâ€…vivo Rat Models of Parkinson's Disease. ChemMedChem, 2009, 4, 1010-1019.	3.2	32
56	Guanine Nucleotide Effects on 8-Cyclopentyl-1,3-[3H]Dipropylxanthine Binding to Membrane-Bound and Solubilized A1Adenosine Receptors of Rat Brain. Journal of Neurochemistry, 1990, 54, 1988-1994.	3.9	30
57	Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A_{2A} Adenosine Receptor Antagonists with Improved Water Solubility. Journal of Medicinal Chemistry, 2011, 54, 877-889.	6.4	30
58	New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides. European Journal of Medicinal Chemistry, 2013, 63, 924-934.	5.5	30
59	The glycoprotein nature of A1 adenosine receptors. Biochemical and Biophysical Research Communications, 1986, 140, 406-413.	2.1	29
60	The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: Application to a lead optimization of a human A3 adenosine receptor antagonist. Bioorganic and Medicinal Chemistry, 2006, 14, 4923-4932.	3.0	29
61	Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligandâ€“receptor recognition process. Bioorganic and Medicinal Chemistry, 2010, 18, 2524-2536.	3.0	29
62	Affinities of barbiturates for the GABA-receptor complex and A1 adenosine receptors: a possible explanation of their excitatory effects. Naunyn-Schmiedeberg's Archives of Pharmacology, 1987, 336, 211-217.	3.0	27
63	A carboxyl-terminal tail peptide of neutrophil chemotactic receptor disrupts its physical complex with G protein. Journal of Leukocyte Biology, 1993, 54, 572-577.	3.3	26
64	Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A2A and A3 receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Bioorganic and Medicinal Chemistry, 2009, 17, 5259-5274.	3.0	26
65	7â€Aminoâ€2â€aryl/heteroâ€arylâ€5â€oxoâ€5,8â€dihydro[1,2,4]triazolo[1,5â€a]pyridineâ€6â€carbonitriles: Synthesis and adenosine receptor binding studies. Chemical Biology and Drug Design, 2019, 94, 1568-1573.	3.2	26
66	Binding thermodynamics at the human A3 adenosine receptor. Biochemical Pharmacology, 2002, 63, 157-161.	4.4	25
67	Novel thiazoleâ€“thiophene conjugates as adenosine receptor antagonists: Synthesis, biological evaluation and docking studies. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1306-1309.	2.2	25
68	Regulation of p42/p44 mitogen-activated protein kinase by the human adenosine A3 receptor in transfected CHO cells. European Journal of Pharmacology, 2001, 420, 19-26.	3.5	24
69	5â€²-Carbamoyl derivatives of 2â€²-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: Affinity, efficacy, and selectivity for A1 receptor from different species. Bioorganic and Medicinal Chemistry, 2008, 16, 336-353.	3.0	24
70	Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido[2,3-d]pyrimidines and quinazolines. Medicinal Chemistry Research, 2018, 27, 756-767.	2.4	24
71	Neuroprotective potential of adenosine A 1 receptor partial agonists in experimental models of cerebral ischemia. Journal of Neurochemistry, 2019, 149, 211-230.	3.9	24
72	Discovery of 7-(Prolinol-N-yl)-2-phenylamino-thiazolo[5,4-d]pyrimidines as Novel Non-Nucleoside Partial Agonists for the A2A Adenosine Receptor: Prediction from Molecular Modeling. Journal of Medicinal Chemistry, 2016, 59, 5922-5928.	6.4	23

#	Article	IF	Citations
73	Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. PLoS ONE, 2018, 13, e0188212.	2.5	23
74	A2A-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand. Drug Development Research, 1998, 45, 190-197.	2.9	22
75	Novel chiral isoxazole derivatives: Synthesis and pharmacological characterization at human Î²-adrenergic receptor subtypes. Bioorganic and Medicinal Chemistry, 2007, 15, 2533-2543.	3.0	22
76	Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 519-525.	3.0	22
77	5â€²-C-Ethyl-tetrazolyl-N⁶-Substituted Adenosine and 2-Chloro-adenosine Derivatives as Highly Potent Dual Acting A₁ Adenosine Receptor Agonists and A₃ Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2015, 58, 2560-2566.	6.4	22
78	Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode. Journal of Chemical Information and Modeling, 2018, 58, 794-815.	5.4	22
79	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonists. Drug Development Research, 2001, 53, 225-235.	2.9	21
80	A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) andN-alkyl andN-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): Different recognition of bovine and human binding sites. Drug Development Research, 2004, 63, 1-7.	2.9	20
81	Exploring Potency and Selectivity Receptor Antagonist Profiles Using a Multilabel Classification Approach: The Human Adenosine Receptors as a Key Study. Journal of Chemical Information and Modeling, 2009, 49, 2820-2836.	5.4	19
82	Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch. Biochemical Pharmacology, 2014, 87, 321-331.	4.4	19
83	Guanosine exerts antiplatelet and antithrombotic properties through an adenosine-related cAMP-PKA signaling. International Journal of Cardiology, 2017, 248, 294-300.	1.7	19
84	7-Nitrobenzofurazan (NBD) derivatives of 5â€²-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A3 adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3023-3026.	2.2	18
85	5,7-Disubstituted-[1,2,4]triazolo[1,5- a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors. European Journal of Medicinal Chemistry, 2016, 108, 529-541.	5.5	18
86	Exploring the Directionality of 5-Substitutions in a New Series of 5-Alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy To Design Novel Human A₃ Adenosine Receptor Antagonists.. Journal of Medicinal Chemistry, 2012, 55, 9654-9668.	6.4	17
87	Effects of Adenosine on Histamine Release from Human Lung Fragments. International Archives of Allergy and Immunology, 1992, 98, 50-56.	2.1	16
88	Synthesis and adenosine receptors binding affinities of a series of 3-arylcoumarins. Journal of Pharmacy and Pharmacology, 2013, 65, 1590-1597.	2.4	16
89	Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A_{2A} Adenosine Receptor Antagonists. Journal of Chemical Information and Modeling, 2013, 53, 1620-1637.	5.4	16
90	Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies. Bioorganic and Medicinal Chemistry, 2014, 22, 1751-1765.	3.0	16

#	Article	IF	Citations
91	Pharmacological characterisation of novel adenosine A3 receptor antagonists. Scientific Reports, 2020, 10, 20781.	3.3	16
92	Peptide G protein agonists from a phage display library. Biochemical Pharmacology, 2003, 65, 961-967.	4.4	15
93	Synthesis of enantiopure Î”2-isoxazoline derivatives and evaluation of their affinity and efficacy profiles at human Î²-adrenergic receptor subtypes. Bioorganic and Medicinal Chemistry, 2006, 14, 4393-4401.	3.0	15
94	Organoruthenium Antagonists of Human A₃ Adenosine Receptors. Chemistry - A European Journal, 2013, 19, 8321-8330.	3.3	15
95	Exploring the Role of N⁶-Substituents in Potent Dual Acting 5â€²-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice. Journal of Medicinal Chemistry, 2017, 60, 4327-4341.	6.4	15
96	Synthesis and Biological Activity of Trisubstituted Adenines as A_{2A}Adenosine Receptor Antagonists. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 1443-1446.	1.1	14
97	8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands. European Journal of Medicinal Chemistry, 2013, 70, 525-535.	5.5	14
98	Structure-Based Optimization of Coumarin hA₃ Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2020, 63, 2577-2587.	6.4	14
99	Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives. Journal of Pharmacy and Pharmacology, 2012, 65, 30-34.	2.4	13
100	Insight into the Interactions between Novel Coumarin Derivatives and Human A₃ Adenosine Receptors. ChemMedChem, 2014, 9, 2245-2253.	3.2	13
101	Scaffold Decoration at Positions 5 and 8 of 1,2,4-Triazolo[1,5-c]Pyrimidines to Explore the Antagonist Profiling on Adenosine Receptors: A Preliminary Structureâ€“Activity Relationship Study. Journal of Medicinal Chemistry, 2014, 57, 6210-6225.	6.4	13
102	The A2B adenosine receptor in MDA-MB-231 breast cancer cells diminishes ERK1/2 phosphorylation by activation of MAPK-phosphatase-1. PLoS ONE, 2018, 13, e0202914.	2.5	13
103	[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype. European Journal of Medicinal Chemistry, 2018, 157, 837-851.	5.5	13
104	New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signalling, 2007, 3, 339-346.	2.2	12
105	The Length and Flexibility of the 2â€Substituent of 9â€Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A_{2A} Adenosine Receptor. ChemMedChem, 2016, 11, 1829-1839.	3.2	12
106	2- and 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosine receptors. Purinergic Signalling, 2005, 1, 173-181.	2.2	11
107	Does the combination of optimal substitutions at the C2-, N5- and N8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A3 adenosine receptors?. Bioorganic and Medicinal Chemistry, 2011, 19, 6120-6134.	3.0	11
108	New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases. European Journal of Medicinal Chemistry, 2018, 151, 199-213.	5.5	11

#	Article	IF	Citations
109	A novel small molecule A2A adenosine receptor agonist, indirubin-3â€²-monoxime, alleviates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes. Biochemical Journal, 2019, 476, 2371-2391.	3.7	11
110	Adenosine receptors and human melanoma. Drug Development Research, 2003, 58, 377-385.	2.9	10
111	Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes. Purinergic Signalling, 2008, 4, 39-46.	2.2	10
112	Receptor crosstalk: haloperidol treatment enhances A2A adenosine receptor functioning in a transfected cell model. Purinergic Signalling, 2010, 6, 373-381.	2.2	10
113	2-(N-Acyl) and 2-N-acyl-N6-substituted analogues of adenosine and their affinity at the human adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1495-1498.	2.2	9
114	Novel Mutants of the Human Î²1-Adrenergic Receptor Reveal Amino Acids Relevant for Receptor Activation. Journal of Biological Chemistry, 2006, 281, 18120-18125.	3.4	9
115	Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold. Bioorganic Chemistry, 2015, 61, 1-6.	4.1	9
116	Synthesis and Evaluation of a New Series of 8â€(2â€Nitroaryl)Xanthines as Adenosine Receptor Ligands. Drug Development Research, 2016, 77, 241-250.	2.9	9
117	Structure-Based Design, Synthesis, and In Vivo Antinociceptive Effects of Selective A₁ Adenosine Receptor Agonists. Journal of Medicinal Chemistry, 2018, 61, 305-318.	6.4	9
118	Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example. MedChemComm, 2019, 10, 1094-1108.	3.4	9
119	Radiation inactivation analysis of the A1 adenosine receptor of rat brain Decrease in radiation inactivation size in the presence of guanine nucleotide. FEBS Letters, 1989, 252, 125-128.	2.8	8
120	Synthesis of (R)-3,4-dihydro-2H-pyran-2-carboxaldehyde: application to the synthesis of potent adenosine A2A and A3 receptor agonist. Tetrahedron Letters, 2009, 50, 2693-2696.	1.4	8
121	New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. Collection of Czechoslovak Chemical Communications, 2011, 76, 1379-1393.	1.0	8
122	Synthesis and pharmacological characterization of novel xanthine carboxylate amides as A2A adenosine receptor ligands exhibiting bronchospasmolytic activity. Bioorganic Chemistry, 2016, 65, 26-37.	4.1	8
123	Adenosine Receptor Ligands: Coumarinâ€“Chalcone Hybrids as Modulating Agents on the Activity of hARs. Molecules, 2020, 25, 4306.	3.8	8
124	Synthesis of 2-Azido-(R)-N⁶-p-hydroxyphenylisopropyladenosine (R-AHPIA) as Potential Photoaffinity Probe for A₁Adenosine Receptors. Nucleosides & Nucleotides, 1986, 5, 213-222.	0.5	7
125	G-protein-coupled A1 adenosine receptors in coated vesicles of mammalian brain: Characterization by radioligand binding and photoaffinity labelling. Cellular Signalling, 1992, 4, 737-745.	3.6	7
126	The interaction of N-formyl peptide chemoattractant receptors with the membrane skeleton is energy-dependent. Cellular Signalling, 1994, 6, 943-947.	3.6	7

#	Article	IF	Citations
127	Physical coupling of N-formyl peptide chemoattractant receptors to G protein is unaffected by desensitization. Biochemical Pharmacology, 1994, 48, 1297-1300.	4.4	7
128	Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists. Il Farmaco, 2005, 60, 299-306.	0.9	7
129	Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A2A AR ligands with in vivo efficacy against animal model of Parkinsonâ€™s disease. Bioorganic Chemistry, 2019, 87, 601-612.	4.1	7
130	Molecular modelling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A3 adenosine receptor ligands. Purinergic Signalling, 2006, 2, 589-594.	2.2	6
131	Inhibitors of membranous adenylyl cyclases with affinity for adenosine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 349-352.	3.0	6
132	The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives. PLoS ONE, 2015, 10, e0143504.	2.5	6
133	Coumarins and adenosine receptors: New perceptions in structureâ€“affinity relationships. Chemical Biology and Drug Design, 2018, 91, 245-256.	3.2	5
134	A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?. Molecules, 2022, 27, 2386.	3.8	5
135	Discovery of 2-aminoimidazole and 2-amino imidazolyl-thiazoles as non-xanthine human adenosine A3receptor antagonists: SAR and molecular modeling studies. MedChemComm, 2018, 9, 676-684.	3.4	4
136	New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity. Bioorganic Chemistry, 2019, 92, 103183.	4.1	4
137	Targeting G Proteinâ€Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A 3 Adenosine Receptor. ChemMedChem, 2020, 15, 1909-1920.	3.2	4
138	Bronchospasmolytic activity and adenosine receptor binding of some newer 1,3â€dipropylâ€8â€phenyl substituted xanthine derivatives. Chemical Biology and Drug Design, 2020, 95, 600-609.	3.2	4
139	A3 adenosine receptors: Synthesis and biological evaluation of new potent and selective ligands. , 2005, , .		4
140	Agonists activate different A2B adenosine receptor signaling pathways in MBA-MD-231 breast cancer cells with distinct potencies. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1515-1521.	3.0	3
141	Adenosine Receptor Biology in the Central Nervous System. , 2017, , 3-22.		2
142	Pharmacology and Molecular Biology of A3 Adenosine Receptors. , 2010, , 49-58.		1
143	Synthesis, Biological Studies and Molecular Modeling Investigation of 1,3-Dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-Tetrahydro-[1,2,4]-triazolo-[3,4-f]-purines as Potential Adenosine Receptor Antagonists.. ChemInform, 2005, 36, no.	0.0	0
144	Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy. Molecules, 2019, 24, 3661.	3.8	0

#	Article	IF	Citations
145	Potent and selective A₃ adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties. RSC Medicinal Chemistry, 2021, 12, 254-262.	3.9	0